|
Gene: E4F1 |
Gene summary for E4F1 |
Gene summary. |
Gene information | Species | Human | Gene symbol | E4F1 | Gene ID | 1877 |
Gene name | E4F transcription factor 1 | |
Gene Alias | E4F | |
Cytomap | 16p13.3 | |
Gene Type | protein-coding | GO ID | GO:0000122 | UniProtAcc | Q66K89 |
Top |
Malignant transformation analysis |
Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
Malignant transformation involving gene list. |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
1877 | E4F1 | LZE4T | Human | Esophagus | ESCC | 2.31e-05 | 2.46e-01 | 0.0811 |
1877 | E4F1 | LZE7T | Human | Esophagus | ESCC | 2.39e-09 | 5.11e-01 | 0.0667 |
1877 | E4F1 | LZE20T | Human | Esophagus | ESCC | 2.61e-05 | 2.57e-01 | 0.0662 |
1877 | E4F1 | LZE24T | Human | Esophagus | ESCC | 1.44e-07 | 2.55e-01 | 0.0596 |
1877 | E4F1 | P1T-E | Human | Esophagus | ESCC | 1.25e-19 | 7.13e-01 | 0.0875 |
1877 | E4F1 | P2T-E | Human | Esophagus | ESCC | 1.80e-31 | 5.88e-01 | 0.1177 |
1877 | E4F1 | P4T-E | Human | Esophagus | ESCC | 1.40e-15 | 3.68e-01 | 0.1323 |
1877 | E4F1 | P5T-E | Human | Esophagus | ESCC | 1.42e-13 | 3.01e-01 | 0.1327 |
1877 | E4F1 | P8T-E | Human | Esophagus | ESCC | 6.69e-12 | 2.47e-01 | 0.0889 |
1877 | E4F1 | P9T-E | Human | Esophagus | ESCC | 1.78e-09 | 2.16e-01 | 0.1131 |
1877 | E4F1 | P10T-E | Human | Esophagus | ESCC | 2.39e-13 | 2.36e-01 | 0.116 |
1877 | E4F1 | P11T-E | Human | Esophagus | ESCC | 6.11e-12 | 6.06e-01 | 0.1426 |
1877 | E4F1 | P12T-E | Human | Esophagus | ESCC | 8.01e-24 | 5.11e-01 | 0.1122 |
1877 | E4F1 | P15T-E | Human | Esophagus | ESCC | 1.92e-19 | 4.34e-01 | 0.1149 |
1877 | E4F1 | P16T-E | Human | Esophagus | ESCC | 1.78e-15 | 2.53e-01 | 0.1153 |
1877 | E4F1 | P17T-E | Human | Esophagus | ESCC | 1.96e-07 | 3.63e-01 | 0.1278 |
1877 | E4F1 | P19T-E | Human | Esophagus | ESCC | 4.75e-04 | 4.39e-01 | 0.1662 |
1877 | E4F1 | P20T-E | Human | Esophagus | ESCC | 9.38e-27 | 5.79e-01 | 0.1124 |
1877 | E4F1 | P21T-E | Human | Esophagus | ESCC | 1.21e-15 | 2.77e-01 | 0.1617 |
1877 | E4F1 | P22T-E | Human | Esophagus | ESCC | 4.84e-16 | 2.97e-01 | 0.1236 |
Page: 1 2 3 4 |
Transcriptomic changes along malignancy continuum. |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
Figure of enriched GO biological processes. |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | |
Colorectum | SER | |
Colorectum | MSS | |
Colorectum | MSI-H | |
Colorectum | FAP |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
Enriched GO biological processes. |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:000734615 | Esophagus | ESCC | regulation of mitotic cell cycle | 293/8552 | 457/18723 | 8.00e-16 | 5.64e-14 | 293 |
GO:00062604 | Esophagus | ESCC | DNA replication | 181/8552 | 260/18723 | 3.55e-15 | 2.05e-13 | 181 |
GO:000734611 | Liver | HCC | regulation of mitotic cell cycle | 255/7958 | 457/18723 | 4.96e-09 | 1.30e-07 | 255 |
GO:00062601 | Liver | HCC | DNA replication | 146/7958 | 260/18723 | 5.68e-06 | 7.02e-05 | 146 |
GO:00073469 | Oral cavity | OSCC | regulation of mitotic cell cycle | 266/7305 | 457/18723 | 3.87e-17 | 3.41e-15 | 266 |
GO:00062603 | Oral cavity | OSCC | DNA replication | 159/7305 | 260/18723 | 3.25e-13 | 1.59e-11 | 159 |
GO:000734614 | Oral cavity | LP | regulation of mitotic cell cycle | 163/4623 | 457/18723 | 7.64e-08 | 2.56e-06 | 163 |
GO:000626011 | Oral cavity | LP | DNA replication | 97/4623 | 260/18723 | 3.67e-06 | 7.75e-05 | 97 |
Page: 1 |
Enriched KEGG pathways. |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 2 |
Top |
Somatic mutation of malignant transformation related genes |
Annotation of somatic variants for genes involved in malignant transformation |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
E4F1 | SNV | Missense_Mutation | novel | c.2311N>A | p.Ala771Thr | p.A771T | Q66K89 | protein_coding | tolerated(0.61) | benign(0.006) | TCGA-E6-A1LX-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
E4F1 | SNV | Missense_Mutation | rs749141504 | c.650G>A | p.Arg217His | p.R217H | Q66K89 | protein_coding | deleterious(0.01) | possibly_damaging(0.841) | TCGA-EO-A22R-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
E4F1 | SNV | Missense_Mutation | novel | c.1580N>A | p.Arg527His | p.R527H | Q66K89 | protein_coding | tolerated(0.06) | possibly_damaging(0.59) | TCGA-EO-A3B0-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
E4F1 | deletion | Frame_Shift_Del | c.2148delC | p.Glu717ArgfsTer3 | p.E717Rfs*3 | Q66K89 | protein_coding | TCGA-SL-A6JA-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |||
E4F1 | SNV | Missense_Mutation | rs768604168 | c.1534N>A | p.Val512Ile | p.V512I | Q66K89 | protein_coding | tolerated(0.23) | possibly_damaging(0.824) | TCGA-4R-AA8I-01 | Liver | liver hepatocellular carcinoma | Male | >=65 | I/II | Unknown | Unknown | PD |
E4F1 | SNV | Missense_Mutation | novel | c.1226C>G | p.Ala409Gly | p.A409G | Q66K89 | protein_coding | tolerated(0.39) | benign(0.007) | TCGA-BC-A10S-01 | Liver | liver hepatocellular carcinoma | Male | >=65 | III/IV | Unknown | Unknown | PD |
E4F1 | SNV | Missense_Mutation | c.2278G>A | p.Glu760Lys | p.E760K | Q66K89 | protein_coding | deleterious(0) | possibly_damaging(0.657) | TCGA-38-4625-01 | Lung | lung adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
E4F1 | SNV | Missense_Mutation | c.245N>T | p.Cys82Phe | p.C82F | Q66K89 | protein_coding | deleterious(0) | probably_damaging(0.998) | TCGA-38-4629-01 | Lung | lung adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | PD | |
E4F1 | SNV | Missense_Mutation | c.520N>T | p.Ala174Ser | p.A174S | Q66K89 | protein_coding | tolerated(0.7) | benign(0.001) | TCGA-55-7727-01 | Lung | lung adenocarcinoma | Male | >=65 | III/IV | Unknown | Unknown | SD | |
E4F1 | SNV | Missense_Mutation | novel | c.1526N>T | p.His509Leu | p.H509L | Q66K89 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-78-7155-01 | Lung | lung adenocarcinoma | Male | >=65 | I/II | Chemotherapy | carboplatin | PD |
Page: 1 2 3 4 5 6 7 8 |
Top |
Related drugs of malignant transformation related genes |
Identification of chemicals and drugs interact with genes involved in malignant transfromation |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |